Autologous Dendritic Cell Therapy
Recurrent Metastatic Ewing Sarcoma and Osteosarcoma (Pediatric)
Phase 2Active
Key Facts
Indication
Recurrent Metastatic Ewing Sarcoma and Osteosarcoma (Pediatric)
Phase
Phase 2
Status
Active
Company
About CellXLife
CellXLife is advancing a dendritic cell-based cancer vaccine with compelling long-term survival data from an initial Phase I trial in pediatric bone cancer. The therapy, which leverages immunological memory, demonstrated a 62.5% survival rate beyond 15 years in a small, high-risk patient cohort. The company is preparing for a Phase II trial and benefits from Orphan Drug Designation, which may facilitate a faster regulatory pathway. Its platform also has potential applications in other solid tumors, including breast, ovarian, and lung cancers.
View full company profile